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Abstract
Background: To evaluate changes in endothelial progenitor cells (EPCs) and cytokines in patients with diabetic foot
ulceration (DFU) in association with wound healing.
Methods: We studied healthy subjects, diabetic patients not at risk of DFU, at risk of DFU and with active DFU. We
prospectively followed the DFU patients over a 12-week period. We also investigated similar changes in diabetic
rabbit and mouse models of wound healing.
Results: All EPC phenotypes except the kinase insert domain receptor (KDR)+CD133+ were reduced in the at risk
and the DFU groups compared to the controls. There were no major EPC differences between the control and not at
risk group, and between the at risk and DFU groups. Serum stromal-cell derived factor-1 (SDF-1) and stem cell factor
(SCF) were increased in DFU patients. DFU patients who healed their ulcers had lower CD34+KDR+ count at visits 3
and 4, serum c-reactive protein (CRP) and granulocyte-macrophage colony-stimulating factor (GM-CSF) at visit 1,
interleukin-1 (IL-1) at visits 1 and 4. EPCs tended to be higher in both diabetic animal models when compared to their
non-diabetic counterparts both before and ten days after wounding.
Conclusions: Uncomplicated diabetes does not affect EPCs. EPCs are reduced in patients at risk or with DFU while
complete wound healing is associated with CD34+KDR+ reduction, suggesting possible increased homing. Low
baseline CRP, IL-1α and GM-CSF serum levels were associated with complete wound healing and may potentially
serve as prognostic markers of DFU healing. No animal model alone is representative of the human condition,
indicating the need for multiple experimental models.
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Introduction
Diabetic foot ulceration (DFU) is a major health problem with
considerable morbidity and mortality along with heavy financial
burden for health care services [1]. Although neuropathy,
vascular disease and trauma are the main factors that lead to
the development of DFU, impaired wound healing is the main
factor that leads to development of chronic wounds and lower
extremity amputations [2]. Previous studies in our unit have
shown that pre-existing inflammation and aberrant growth
factor levels are directly associated with failure to heal an ulcer
[3].
Bone marrow-derived endothelial progenitor cells (EPCs)
play an important role in angiogenesis and in maintaining the
integrity and function of vascular endothelium, as they are
mobilized either in response to tissue ischemia or by various
cytokines to integrate into new and existing blood vessels [4,5].
Initial studies showed severely reduced EPC levels in diabetic
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patients with peripheral arterial disease (PAD) and patients
with diabetic vascular complication especially in patients with
foot lesions [6,7]. Recent studies reported reduced EPC levels
in diabetes irrespective of the presence or absence of
macrovascular disease while the presence of macrovascular
disease in non-diabetic subjects did not affect EPC levels [8].
Although the role of EPCs in DFU healing in human subjects
has not been explored, preliminary studies in diabetic patients
with critical limb ischemia (CLI) indicated that autologous
transplantation of granulocyte colony-stimulating factor (G-
CSF)-mobilized peripheral blood mononuclear cells (PBMNCs)
improved blood flow and led to complete wound healing [9].
The main aim of the present study was to evaluate changes
that occur in EPCs, growth factors and cytokines in patients
with active DFU and their association with the progression of
wound healing. In order to achieve this, we first conducted a
cross-sectional study that compared differences in four groups:
1) healthy control subjects, 2) diabetic patients without serious
complications, 3) diabetic patients at risk of DFU in the
absence of peripheral arterial disease, and 4) diabetic patients
with DFU. We also conducted a prospective study that followed
the DFU patients over a 12-week period and examined the
progress in wound healing in relationship to changes in EPC
numbers and cytokine expression. We finally extended the
investigation into rabbit and mouse models of diabetic wound
healing.
Research Design and Methods
Subjects
All research subjects were recruited from patients who
attended the Joslin-Beth Israel Deaconess Foot Center. We
studied four groups: healthy control subjects; diabetic patients
not at risk of DFU; patients with peripheral neuropathy severe
enough to put them at risk of DFU according to previously
published criteria [10]; and diabetic patients with chronic DFU
at the forefoot (defined as a clinically non-infected ulcer that
was present for at least four weeks and extended through the
dermis and into subcutaneous tissue but without exposure
bone or joint capsule). Exclusion criteria were: Clinically
present PAD, end stage renal disease, active Charcot
neuroarthropathy, severe heart failure and/or any other serious
illnesses.
We also examined discarded skin specimens of age and sex
matched healthy, non-diabetic subjects and diabetic patients
with peripheral neuropathy who underwent foot surgery. Seven
healthy, non-diabetic subjects [age 55 ±18 years (mean±sd), 3
males] and 10 diabetic patients (61±10 years, 6 males) were
included. The study was approved by the IRB of the Beth Israel
Deaconess Medical Center (2006-P-000335) and all
participants signed informed consent.
Methods
Baseline visit.  Subjects in the first three groups were seen
once while DFU patients were followed for twelve weeks and
were seen for a total of 3 additional visits every four weeks.
DFU treatment was provided according to standard guidelines
[11].
Clinical and laboratory assessments.  The measurements
of inflammatory cytokines and growth factors were performed
with a Luminex 200 apparatus (Luminex Corporation Austin,
TX) and Millipore multiplex immunoassay panels (Millipore
Corporation, Chicago, IL).
Evaluation of Diabetic Neuropathy and Peripheral
Arterial Disease.  Neuropathy symptoms were evaluated by
using a Neuropathy Symptom Score (NSS), clinical signs by
using a Neuropathy Disability Score (NDS), assessment of
Vibration Perception Threshold and Cutaneous Perception
Threshold using a set of twelve Semmes-Weinstein
monofilaments ranging from 2.83 to 10 g. Patients who were
defined at high risk of foot ulceration had NDS≥5 and were
unable to feel a 5.07 Semmes-Weinstein monofilament [10].
Peripheral Arterial Disease was assessed clinically; patients
with Ankle Brachial Index (ABI) ≤0.7, absence of foot pulses
and/or claudication were excluded from the study.
Vascular Reactivity Tests.  The vascular reactivity of the
forearm skin microcirculation was evaluated by Laser Doppler
perfusion imaging measurements before and after the
iontophoresis with acetylcholine chloride (Ach, endothelium-
dependent vasodilation) and sodium nitroprusside (SNP,
endothelium-independent vasodilation) as previously described
[12]. The Nerve Axon Reflex-Related Vasodilation was
performed by using a single point Laser Probe and the Moor
DRT4 System [12]. The flow mediated brachial artery dilation
(FMD, endothelium dependent) and nitroglycerine-induced
dilation (NID, endothelium independent) were measured in
accordance with published guidelines [13].
Evaluation of Oxy- and Deoxy-Hemoglobin.  Data were
collected with a HyperMed System (HyperMed, Inc., Burlington,
MA) as previously described [14].
Flow cytometry measurements of EPCs.  The
measurements of the various EPC phenotypes were performed
at the Beth Israel Deaconess Flow Cytometry Core Facility.
Immunofluorescent cell staining was performed on peripheral
blood with the use of the fluorescent conjugated antibody
CD34–fluorescein isothiocyanate (FITC, Becton Dickinson),
type 2 vascular endothelial growth factor receptor 2 (VEGF-
R2)/KDR (kinase insert domain receptor)-phycoerythrin (PE,
Miltenyi Biotec), CD133-allophycocyanin (APC, Miltenyi Biotec)
and CD45-Peridinin Chlorophyll Protein (PerCP, Miltenyi
Biotec) according to standard techniques. We employed a
hierarchical gating strategy to count negative or low expressing
CD45 cells (CD45dim). 1.000.000 events per sample were
acquired using a FACS LSR II analyzer (Becton Dickinson,
Franklin Lakes, NJ, USA) and the results were analyzed using
the Beckman Coulter Kaluza analysis software (Beckman
Coulter Inc., Brea, CA, USA). An example of measurements in
a patient with DFU and a healthy control subject are presented
in Figure 1. The same methods were employed for the animal
models.
Forearm Skin Biopsies.  One two-millimeter forearm skin
punch biopsy was taken from a different cohort of control and
diabetic subjects as previously described [3]. 5μm frozen
sections were immunostained with anti-human stromal cell
derived factor-1 (SDF-1, 1:50; Abcam, Cambridge, MA, USA)
and anti-human CXCR4 (1:100; Chemicon International,
EPCs, Cytokines and Wound Healing
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Temecula, CA). A semi-quantitative analysis was performed for
intensity (grade: 1=faint ; 2=low; 3=medium; 4=strong). The
presence of staining in stromal cells (grade: 1 for 5-30% of
cells expressing the antibody; 2 for 30-60%; 3 for more than
60%) and in endothelial cells (grade: 1 for no stain; 2 for
positive endothelial cells staining) was also evaluated.
Animal Models.  Mice: Diabetes was induced in 12-week
old C57BL6/J mice with 50 mg/kg STZ intraperitoneally for 5
consecutive days) in citrate buffer (0.1M), while non-diabetic
controls received vehicle alone. Fasting blood glucose was
monitored one week post treatment, and mice with blood
glucose over 250 mg/dL were considered diabetic. After 8
weeks, two 6 mm excisional wounds were createdn the shaved
skin dorsum of the animals. Wound healing progress was
measured daily by acetate tracing during 10 days.
Rabbits: Rabbits were made diabetic by alloxan (75mg/kg)
to achieve fasting blood glucose over 250 mg/dL. Ten days
after induction of diabetes, full thickness 6mm punch biopsy
circular wounds were created in rabbit ears as previously
described [15]. Wound healing was monitored over a ten day
period. All animal studies were approved by the Beth Israel
Deaconess Medical Center Institutional Animal Care and Use
Committee (IACUC).
Data analysis.  The Minitab statistical package (State
College, PA) was used. For parametrically distributed data, the
analysis of variance test was used, followed by the Fisher test
to identify differences among the various groups. For
nonparametrically distributed data, the Kruskal - Wallis test was
used. For the comparison in changes during the four visits of
the prospective study, the Friedman test was employed. The
Spearman correlation coefficient r was used for the correlation
of different parameters.
Results
Comparisons among the four tested groups
We recruited 131 subjects: 29 healthy control subjects, 39
diabetic (DM) patients not at risk of DFU, 25 DM patients at risk
of DFU and 29 patients with an active DFU ( Table 1). The foot
nerve axon reflex-related vasodilation, a measurement of the c-
nociceptive fibers function, was reduced in all diabetic subjects
when compared to the controls and was further reduced in the
DFU group when compared to the other two diabetic groups
(p<0.0001). The vasodilatory response to acetylcholine, a
measurement of the foot skin endothelium function, was
reduced in the diabetic patients at risk of DFU (p<0.05). There
were no differences in the dorsum foot skin oxy- and
deoxyhemoglobin and the saturated oxyhemoglobin among the
four groups. FMD was reduced in the DM patients at risk of
DFU and the DFU patients when compared to the other two
groups (p<0.0001). The differences in serum growth factors
Figure 1.  An example of flow cytometric analysis of human peripheral blood sorted on CD45dim cells in a patient with DFU
(A) and a healthy control subject (B).  The triple positive phenotype (CD34+/KDR+/CD133+) was determined by gating the CD133+
cells on the CD34+/KDR+. 1.000.000 events per sample were acquired and the counts for each phenotype are shown in the picture.
Smaller counts in all phenotypew were observed in the diabetic patient (A) when compared to the healthy subject (B) in the double
and triple measurements.
doi: 10.1371/journal.pone.0083314.g001
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and inflammatory cytokines are shown in Table 2. DFU patients
had higher levels of growth related oncogene (GRO, p<0.02),
interleukin-8 (IL-8, p<0.01), macrophage-derived chemokine
(MDC, p<0.02), tumor necrosis factor alpha (TNFα, p<0.0001),
c-reactive protein (CRP, p<0.01), SDF-1 (p<0.0001) and stem
cell factor (SCF, p<0.0001).
For technical reasons, reliable flow cytometry results were
available in 25 controls, 28 DM patients not at risk of DFU, 20
DM patients at risk of DFU and 25 DM patients with DFU
(Figure 1). There were no major differences between the
control subjects and the not at risk of DFU group (Table 2). In
addition, there were no major differences between the at risk of
DFU and the DFU groups except the CD34+KDR+ phenotype
was reduced in the at risk of DFU group. Compared to the
controls, all tested EPC phenotypes except for the KDR
+CD133+ were reduced in the at risk of DFU and the DFU
groups. Patients not at risk of DFU also had higher counts of
most EPC phenotypes when compared to the other two
diabetic groups even though the differences were not as
prominent as the ones observed with the control group.
The relationship between EPC measurements, FMD and
biochemical measurements of inflammation and endothelial
dysfunction was evaluated by performing correlation and
evaluating the correllation coefficient r. For this, all subjects in
all four groups were considered as one group. Positive
correlations were observed between FMD and all flow
cytometry measurements (CD34+: r=0.32, p<0.01, CD34+KDR+:
r=0.31, p<0.01, CD34+CD133+: r=0.26, p<0.05, KDR+CD133+:
r=0.28, p<0.01, CD34+KDR+CD133+: r=0.31, p<0.05). Positive
correlations were also observed between HDL and KDR
+CD133+ (r=0.48, p<0.0001) and CD34+KDR+CD133+ (r=0.22,
p<0.05). A negative correlation existed between CD34+ and
TNFα (r= -0.22, p<0.05), while strong positive correlations were
observed between KDR+CD133+ and serum epidermal growth
factor (EGF, r=0.33, p<0.05), E-Selectin (r=0.67, p<0.0001)
and intercellular adhesion molecule-1 (ICAM, r=0.42,
p<0.0001). No correlations were observed between HbA1c
levels and EPC measurements.
Follow up results in the patients with DFU
The patients with DFU were seen four times every four
weeks for a total period of 12 weeks. Complete wound healing
was achieved in four patients during this period while two more
patients completely healed in the three months after the exit
visit. The most important differences between the patients who
completely healed their ulcers during the study period and
those who did not, are shown in Figures 2 and 3. Thus,
although there were no differences in all EPC measurements at
baseline, patients who healed their ulcers had lower
CD34+KDR+ counts at visits 3 and 4 (Figure 2B, p<0.05),
marginally lower CD34+ at visit 3 (Figure 1A, p=0.062) and
CD34+CD133+ at visit 4 (Fig, 2C, p=0.066). Patients who
healed their ulcers also had lower serum CRP at visit 1 (Figure
3A, p<0.05), lower interleukin-1 alpha (IL-1α) at visit 1 (Figure
3B, p<0.05) and visit 4 (p<0.05), lower Granulocyte-
Macrophage Colony-Stimulating Factor (GM-CSF) at visit 1
(Figure 3C, p<0.05) and marginally lower GM-CSF at visit 4
(p=0.072).
Table 1. Comparisons in subject demographics among the
four tested groups using the Analysis of Variance (ANOVA)
test for parametrically distribuited data and the Kruskal -
Wallis test for nonparametrically distributed data.
 Controls(C)
DM-not at
risk of DFU
(NR)
DM- at risk
of DFU (R) DM-DFU(DFU)
No 38 39 25 29
Age (years) 58 ± 10 62 ± 11 62 ± 9 56 ± 9
Males (%) 24 (63) 22 (56) 16 (64) 23 (79)
BMI a 26.9 ± 7.1 31.5 ± 5.2 31.1 ± 6.4 33.5 ± 5.7
DM Type (1/2) - 8/31 7/18 8/21
DM Duration (years) b - 15 ± 14 26 ± 16 15 ± 9
HbA1c c (%) cSI,
IFCC-recommended
units (mmol/mol)
5.7 ± 0.439 ±
4.4
7.0 ±
0.753 ±
7.7
7.5 ±
1.258 ±
13.1
8.6 ± 2.270 ±
24.0
Fasting Blood
Glucose (mg/dl) c 88 ± 10 116 ± 36 124 ± 52 168 ± 95
Systolic Blood
Pressure (mmHg) d 121 ± 15 120 ± 12 129 ± 17 127 ± 14
Diastolic Blood
Pressure (mmHg) 71 ± 9 72 ± 9 72 ± 10 71 ± 11
Creatinine (mg/dl) e 0.9 ± 0.2 1.0 ± 0.3 1.3 ± 0.4 1.3 ± 0.5
Total Cholesterol f 200 ± 37 166 ± 29 153 ± 44 174 ± 41
HDL Cholesterol g 62 ± 20 57 ± 18 45 ± 15 50 ± 10
LDL Cholesterol a 112 ± 31 84 ± 21 79 ± 31 92 ± 34
Triglycerides 143 ± 88 135 ± 75 153 ± 97 161 ± 87
Neuropathy Symptom
Score (NSS) h 0 ± 1 2 ± 3 5 ± 4 5 ± 4
Neuropathy Disability
Score (NDS) i 0 ± 0 2 ± 2 13 ± 6 15 ± 6
Vibration Perception
Threshold (volts) i 8 ± 4 16 ± 10 39 ± 15 44 ± 12
Semmes-Weinstein
Monofilaments h 3.93 ± 0.28
4.24 ±
0.61
5.95 ±
1.26 6.46 ± 0.76
Foot Nerve Axon
Reflex-Related
Vasodilation (NARV)
(%) j
40 (20 : 81) 16 (1 : 49) 17 (3 : 41) 5 (-8 : 12)
Foot Endothelium
Dependent
Vasodilation (ACh
response) (%) k
28 (12 : 43) 24 (8 : 47) 11 (5 : 22) 20 (5 : 35)
Foot Endothelium
Independent
Vasodilation (SNP
response) (%)
25 (16 : 53) 33 (19 :62) 21 (8 : 34) 20 (6 : 51)
Dorsum Foot Oxy-Hb
(AU) 32 (22 : 45)
41 (25 :
53)
29 (23 :
42) 36 (25 : 55)
Dorsum Foot Deoxy-
Hb (AU) 48 (32 : 65)
53 (43 :
62)
46 (34 :
57) 47 (37 : 60)
Dorsum Foot O2 Hb
Saturation (%) 42 (33 : 48)
39 (31 :
58)
42 (31 :
51) 45 (38 : 53)
Flow Mediated
Vasodilation (FMD,
%) e
7.5 ± 2.5 6.7 ± 2.4 4.2 ± 2.1 4.9 ± 2.2
EPCs, Cytokines and Wound Healing
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The flow cytometry, serum growth factors and cytokine
measurements in all DFU patients, irrespective of the healing
outcome, at all four visits during the 12-week study period are
summarized in Table 3. The only change that was present was
an increase in the KDR+CD133+ EPCs in the third visit when
compared to baseline (p<0.05). There were no other significant
changes in any other measurements. The changes in the foot
ulcer area during the 12-week study period showed significant
correlation with the following baseline measurements: FMD
(r=-0.39, p=0.05), oxygen saturation in the periwound area
(r=0.45, p<0.05) and vascular cell adhesion molecule-1
(VCAM, r=0.39, p=0.051). In addition, changes in the foot ulcer
area were associated with changes in the CD34+ during the
first four weeks of the study (r=0.53, p<0.05). No other
additional correlations were observed between changes in the
ulcer area and changes in the measured cytokines and growth
factors.
Forearm skin biopsies
We evaluated the expression of SDF-1 and its receptor
CXCR4 in the forearm skin biopsies taken from a different
cohort of subjects that participated in another study. We
evaluated biopsies from 12 healthy control subjects and 57 DM
patients (10 non-neuropathic and 47 neuropathic). As there
were no differences between non-neuropathic and neuropathic
patients, all DM patients were evaluated as one group.
SDF-1 was expressed by stromal and endothelial cells
(Figures 4A and 4B). The number of SDF-1 postive stromal
Table 1 (continued).
 Controls(C)
DM-not at
risk of DFU
(NR)
DM- at risk
of DFU (R) DM-DFU(DFU)
Nitroglycerin Induced
Vasodilation (NID, %)
l
15.3 ± 5.7 14.9 ± 4.0 11.2 ± 5.5 13.9 ± 4.0
Ankle Brachial Index %1.1 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2
Statin [n, (%)] a 7 (18%) 26 (67%) 18 (72%) 16 (55%)
Angiotensin
Converting Enzyme
inhibitors /
Angiotensin II
Receptor Blocker [n,
(%)] m
3 (8%) 17 (44%) 13 (52%) 20 (69%)
Insulin [n, (%)] n -- 15 (38%) 16 (64%) 24 (83%)
Oral hypoglycemic [n,
(%)] -- 23 (59%) 9 (36) 10 (35)
Mean ± sd or median (25-75 interquartiles)
a: C vs. NR, R, U: p<0.0001; b: R vs. NR, U: p<0.01; c: C vs. NR, R, U; U vs. NR,
R: p<0.0001; d: C vs R; NR vs R, U: p<0.05; e: C, NR vs. R, U: p<0.0001; f: C vs.
NR, R, U; R vs. U: p<0.0001; g: C vs. R, U; NR vs. R: p=0.001; h: C vs. NR, R, U;
NR vs. R, U: p<0.0001; i: C, NR vs. R, U; R vs. U: p< 0.0001; j: C vs. NR, R, U; U
vs. NR, R: p< 0.0001; k: C vs. R: p<0.05; l: C vs. R, U; NR vs. R: p<0.02; m: C vs.
NR, R, U; NR vs. U: p<0.0001; n: NR vs. R, U: p=0.001
doi: 10.1371/journal.pone.0083314.t001
Table 2. Comparisons in flow cytometry, growth factor and
cytokine results among the four tested groups.
 Controls(C)
DM-not at
risk of DFU
(NR)
DM- at risk
of DFU(R) DM-DFU(DFU)
CD34+ a 904 (240 :3008)
825 (289 :
2128)
160 (75 :
345) 172 (59 : 740)
CD34+KDR+ b 129 (83 : 479) 91 (39 :225)
27 (19 :
38) 42 (20 : 175)
CD34+CD133+ c 117 (48 : 372) 104 (16 :163)
30 (18 :
43) 61 (15 : 133)
KDR+CD133+ 52 (13 : 175) 45 (7: 158) 25 (12 :35) 36 (10 : 93)
CD34+KDR+CD133+
d 18 (6 : 55) 11 (4 : 24) 6 (3 : 11) 3 (2 : 8)
Platelet-Derived
Growth Factor-AA
(ng/ml) e
5.9 (3.7 : 7.4) 6.1 (4.0 :8.8)
4.3 (2.8 :
6.5) 7.7 (4.5 : 13.7)
Platelet-Derived
Growth Factor- AB-
BB (ng/ml)
36.7 (22.8 :
67.3)
43.6 (22.7 :
75.9)
19.8 (10.3 :
60.0)
50.9 (25.8 :
83.5)
EGF (pg/ml) 37.0 (16.0 :55.5)
41.0 (24.5 :
118.0)
28.0 (12.0 :
47.0)
36.5 (14.0 :
99.3)
Fibroblast Growth
Factor-2 (pg/ml)
17.1 (7.6 :
37.7)
17.2 (8.2 :
35.0)
16.6 (9.7 :
48.1)
20.0 (18.9 :
38.2)
VEGF (pg/ml) 173 (92 : 268) 150 (117 :211)
161 (47 :
266)
185 (103 :
253)
Insulin (pg/ml) f 415 (228 :698)
576 (284 :
1016)
1190 (646 :
1948)
468 (256 :
957)
Leptin (ng/ml)g 7.7 (2.9 :17.1)
9.0 (4.3 :
25.9)
18.0 (8.5 :
41.8)
13.1 (7.3 :
30.5)
G-CSF (pg/ml) 30.7 (15.8 :42.0)
32.1 (22.5 :
49.7)
36.1 (23.2 :
45.4)
32.7 (25.2 :
43.5)
GM-CSF (pg/ml) 1.7 (1.2 : 4.5) 1.6 (1.2 :4.5)
3.81 (0.85 :
17.3) 2.3 (1.5 : 3.5)
Eotaxin (pg/ml) 139 (90 : 199) 177 (127 :216)
149 (91 :
206)
167 (107 :
202)
GRO (pg/ml)h 565 (377 :967)
665 (499 :
928)
531 (335 :
669)
840 (618 :
1261)
IFN γ (pg/ml) 1.72 (1.28 :5.97)
3.53 (1.69 :
7.99)
2.20 (0.40 :
10.40)
2.45 (1.72 :
5.49)
Interleukin-6 (pg/ml) 4.38 (0.83 :16.02)
2.56 (1.53 :
10.78)
5.94 (1.48 :
10.02)
7.15 (3.61 :
13.90)
IL-8 (pg/ml)i 13.6 (6.6 :23.7)
15.7 (7.0 :
33.0)
11.0 (6.3 :
21.3)
29.5 (17.1 :
57.6)
Monocyte
Chemoattractant
Protein-1(pg/ml) k
464 (336 :
612)
535 (414 :
694)
412 (298 :
602)
605 (444 :
784)
MDC (pg/ml)l 1326 (1047 :1630)
1402
(1027 :
1683)
1320 (966 :
1720)
1667 (1370 :
1962)
TNFα (pg/ml)m 9.2 (4.5 :11.3)
9.3 (6.0 :
14.2)
9.9 (7.5 :
18.3)
14.6 (10.8:
22.0)
MMP-9 (ng/ml)n 291 (182 :402)
331 (212 :
471)
249 (190 :
302)
377 (272 :
525)
EPCs, Cytokines and Wound Healing
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cells in the dermis was higher in DM patients when compared
to the control subjects (2.2±0.7 vs 1.7±0.6, p<0.05) while no
differences were observed in endothelial cells (2.3±0.6 vs 2.0 ±
1.0, p=NS). In addition to the number of cells, the intensity of
staining was also higher in the DM patients (3.1±0.7 vs
2.5±0.8, p<0.01).
There were no differences in the number of CXCR4 positive
stromal cells (1.9±0.6 vs 1.7 ±0.6, p=NS) or the intensity of
staining (2.5 ±0.8 vs 2.5±0.8, p=NS) between the two groups.
However its expression tended to be lower in the endothelial
cells of diabetic patients (2.1 ±0.6 vs 2.2±0.6, p=0.069).
Foot skin biopsies
The SDF-1 staining pattern was similar to the one observed
in the forearm biopsies. No differences were observed between
the two groups in the number of positive stromal cells,
endothelial cells or the intensity of staining (p=NS). The
intensity of CXCR4 staining (Figures 4C and 4D) was higher in
the DM group (3±1 vs 4±0, p<0.05) but there were no
differences in the number of positive stromal and endothelial
cells (p=NS) between the two groups.
Animal Models
Both diabetic mice and rabbits had impaired wound healing
ten days post-wounding when compared to their respective
controls (p<0.05). The results of the flow cytometry studies in
both models are shown in Table 4. In general, in both models
Table 2 (continued).
 Controls(C)
DM-not at
risk of DFU
(NR)
DM- at risk
of DFU(R) DM-DFU(DFU)
E-Selectin (ng/ml) 45.0 (32.8 :58.1)
48.5 (36.5 :
64.3)
51.0 (37.0 :
63.8)
38.9 (26.2 :
55.1)
ICAM (ng/ml) 120 (96 : 159) 140 (118 :165)
130 (114 :
209)
141 (109 :
170)
VCAM (ng/ml) 1039 (943 :1318)
1150 (922 :
1291)
1151
(1054 :
1363)
1202 (1016 :
1636)
CRP (μg/ml)o 5.6 (1.7 :14.7)
2.1 (1.2 :
18.8)
7.1 (1.8 :
22.8)
13.0 (5.0 :
53.7)
SDF-1 (pg/ml)m 4.73 (3.0 :6.04)
4.39 (3.21 :
5.86)
4.12 (3.03 :
5.47)
7.60 (5.20 :
10.92)
SCF (pg/ml)p 11.1 (5.5 :21.1)
4.4 (0.9 :
11.5)
15.8 (7.3 :
37.6)
37.4 (12.5 :
63.0)
As the data was nonparametrically distributed the Kruskal - Wallis test was
employed.
Median (25-75 interquartiles), flow cytometry results are presented as events/106
a: C, NR vs. R,U, p<0.0001; b: C vs. R, U; R vs. NR, U: p<0.0001; c: C vs. R, U;
NR vs. R: p<0.005; d: C vs. R, U; NR vs. U: p=0.001; e: U vs. C, R; R vs. NR: p<
0.02; f: R vs. C, NR, U: p<0.01; g: C vs. R, U; R vs. NR: p<0.02; h: U vs. C, R:
p<0.02; i: U vs. C, NR, R: p<0.01; k: R vs. U, NR: p<0.05; l: U vs. C, NR, R:
p=0.02; m: U vs. C, NR, R: p<0.0001; n: R vs. U, NR: p=0.02; o: U vs. C, NR, R:
p<0.01; p: C vs. U; NR vs. C, R, U: p<0.0001
doi: 10.1371/journal.pone.0083314.t002
at both study timepoints (baseline, before wounding, and ten
days post-wounding), all tested phenotypes of EPCs tended to
be higher in diabetic animals when compared to their non-
diabetic counterparts. In the mouse model, the tested
phenotypes showed a tendency to increase ten days post-
wounding in both diabetic and non-diabetic animals. In
contrast, rabbits tended to have lower EPC counts after wound
creation in both the diabetic and non-diabetic state but, in most
cases, this reduction failed to reach statistical significance.
In the mouse model, when all animals were considered as
one group, positive correlations were observed at baseline
between FLK-1+CD133+ and serum levels of ICAM (r=0.44,
p<0.05), VCAM (r=0.68, p<0.001) and tissue plasminogen
activator-1 (tPA-1, r=0.52, p<0.05), CD34+CD133+ and ICAM
(r=0.43, p<0.05), VCAM (r=0.71, p<0.001) and tPA-1 (r=0.44,
p<0.05) and CD34+FLK-1+ and ICAM (r=0.44, p<0.05), VCAM
(r=0.70, p<0.001) and tPA-1 (r=0.45, p<0.05).
In non-diabetic rabbits, at baseline, strong correlations were
observed between KDR+CD133+ and serum levels of interferon
gamma (IFNγ, r= -0.58, p<0.01), IL-8 (r=0.56, p<0.01) and
macrophage-derived chemokine (MDC, r=-0.43, p<0.005),
CD34+CD133+ and GM-CSF (r=0.48, p<0.05) and IL-8 (r=0.56,
p<0.01) and CD34+KDR+ and IL-8 (r=0.47, p<0.05). No
asociations were observed in the diabetic animals.
Discussion
The main findings of the current study are: EPCs were
reduced in diabetic patients with complications and the
presence of DFU had no additional effect; compared to all the
other groups, DFU was associated with higher levels of
numerous inflammatory cytokines at baseline while complete
healing was associated with lower CRP, IL-1α and GM-CSF
levels at baseline; serum SDF-1 levels were increased in DFU
patients, its expression in forearm skin biopsies was increased
in diabetic patients while no major changes were observed in
the expression of its receptor CXCR4 at both forearm and foot
skin specimens; complete wound healing was associated with
a parallel reduction in circulating CD34+KDR+ cells suggesting
enhanced homing of these cells during the healing process;
diabetic mice and rabbits that have impaired wound healing
also had increased EPCs ten days after wounding when
compared to non-diabetic animals, suggesting impaired
trafficking of the progenitor cells.
Previous studies in our unit have shown that conditions that
precede the development of DFU, such as increased
inflammation and aberrant secretion of serum growth factors,
are associated with impaired wound healing [3]. In the present
study, we focused on the factors that are associated with the
healing of an existing DFU. We first focused on EPCs as they
are known to play an important role in wound healing [16] and
are affected by diabetes, especially in the presence of
macrovascular disease [17].
There is currently no consensus about the characteristics of
EPCs and the common thought is that they are comprised of
heterogeneous subpopulations that express various antigens
[18]. The most currently used phenotypic markers are
hematopoietic (CD34), early hematopoietic stem-cell (CD133)
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Figure 2.  Changes in EPCs measurements during the four study visits between the patients who did not heal their ulcers
(NH) and those who did (H).  There were no differences in all EPC measurements at baseline but patients who healed their ulcers
had lower CD34+KDR+ counts at visits 3 and 4 and CD34+CD133+ at visit 4. Data are presented as the median and interquartile
range box.
doi: 10.1371/journal.pone.0083314.g002
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and endothelial [VEGR receptor 2 (also known as KDR in
human and FLK-1 in mice)] [19,20]. In the current study we
have measured all of these phenotypic markers, including
CD34+ that according to some reports are also characterized
as circulating endothelial cells (CECs) [21]. Although none of
the study subjects had macrovascular disease, our results
indicate that patients at risk of DFU and/or with DFU had
reduced counts of most of the studied EPC phenotypes (Table
2). The only difference in EPC measurements between patients
at risk of DFU and patients with DFU was that there were
reduced numbers of CD34+KDR+ cells, in the patients at risk of
DFU. These results indicate that the number of circulating
EPCs is not related to the presence of diabetes but the
presence of neuropathy. Furthermore, in agreement with
previous studies [22], EPCs were associated with FMD,
indicating their role in maintaining endothelial function.
However, the rather low correlation coefficient r between FMD
and all EPC phenotypes indicates a rather weak association
and clearly suggests that there are other factors that affect both
measurements. Finally, in contrast with previous studies [23],
within the DM patients, no correlations were observed between
EPC and HbA1c, clearly indicating that the main factor that
influenced EPC numbers was the presence of diabetic
complications.
Furthermore, we found that the baseline numbers of all EPC
phenotypes were not predictive of complete healing or
reduction of the ulcer size during the 12-week study period
(Table 3). However, patients whose ulcers healed had reduced
Figure 3.  Changes in CRP (3a), IL-1a (3B) and GM-CSF (3C) during the four study visits between the patients who did not
heal their ulcers (NH) and those who did (H).  Data are presented as the median and interquartile range box. Patients who
healed their ulcers had lower serum CRP and GM-CSF at visit 1 and lower IL-1α at visits 1 and 4.
doi: 10.1371/journal.pone.0083314.g003
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Table 3. Sequential flow cytometry, growth factor and
cytokine measurements during the four study visits in the
group of patients with DFU.
 
Visit 1
(Baseline)
Visit 2 (4
weeks)
Visit 3 (8
weeks)
Visit 4 (12
weeks)
Ulcer size, %
reduction from
baseline
100 87 (52-131) 63 (20-112) 48 (18-127)
CD34+ 172 (59 :740)
314 (58 :
1129)
189 (45 :
963)
287 (61 :
1101)
CD34+KDR+ 42 (20 : 175) 72 (20 : 185) 72 (28 : 207) 66 (18 : 243)
CD34+CD133+ 61 (15 : 133) 39 (15 : 122) 43 (17 : 163) 70 (15 : 189)
KDR+CD133+ a 36 (10 : 93) 25 (11 : 153) 52 (21 : 104) 49 (17 : 161)
CD34+KDR+CD133+ 3 (2 : 8) 6 (3 : 12) 5 (2 : 14) 8 (3 : 11)
Foot Endothelium
Dependent
Vasodilation (ACh
response) (%)
20 (5 : 35) 12 (3 : 33) 22 (9 : 30) 19 (8 : 29)
Foot Endothelium
Independent
Vasodilation (SNP
response) (%)
20 (6 : 51) 14 (7 : 36) 22 (8 : 34) 28 (12 : 41)
Oxy-Hb in peri-wound
area (AU) 63 (56 : 74) 57 (47 : 73) 61 (46 : 82) 59 (52 : 80)
Deoxy-Hb in peri-
wound area (AU) 47 (39 : 56) 45 (35 : 59) 47 (34 : 72) 48 (39 : 72)
O2 Hb Saturation in
peri-wound area (%) 58 (54 : 59 ) 57 (53 : 58) 56 (53 : 59) 55 (52 : 60)
Platelet-Derived
Growth Factor-AA
(ng/ml)
7.7 (4.5 :
13.7)
7.3 (5.0 :
11.8)
6.1 (4.0 :
11.6)
7.1 (4.3 :
13.3)
Platelet-Derived
Growth Factor AB-BB
(ng/ml)
50.9 (25.8 :
83.5)
45.7 (27.3 :
66.3)
38.4 (26.4 :
83.1)
45.0 (24.6 :
65.6)
EGF (pg/ml) 36.5 (14.0 :99.3)
31.3 (18.7 :
74.0)
27.9 (17.0 :
43.8)
50.9 (8.2 :
71.2)
Fibroblast Growth
Factor-2 (pg/ml)
20.0 (18.9 :
38.2)
16.2 (12.1 :
28.7)
22.9 (11.4 :
25.3)
18.9 (12.1 :
31.0)
VEGF (pg/ml) 185 (103 :253)
185 (114 :
228)
211 (74 :
353)
154 (86 :
382)
Insulin (pg/ml) 468 (256 :957)
710 (304 :
39805)
678 (404 :
2353)
601 (242 :
2088)
Leptin (ng/ml) 13.1 (7.3 :30.5)
15.8 (10.3 :
24.3)
14.1 (8.6 :
17.8)
13.1 (9.1 :
24.7)
G-CSF (pg/ml) 32.7 (25.2 :43.5)
33.9 (27.7 :
38.8
29.4 (23.6 :
40.4)
30.6 (19.4 :
43.7)
GM-CSF (pg/ml) 2.3 (1.5 :3.5)
1.83 (0.91 :
3.36)
1.6 (1.1 :
2.5) 2 (1 : 3)
Eotaxin (pg/ml) 167 (107 :202)
133 (93 :
207)
159 (73 :
206)
149 (108 :
212)
GRO (pg/ml) 840 (618 :1261)
797 (542 :
1377)
1027 (580 :
1281)
853 (564 :
1203)
IFN γ (pg/ml) 2.45 (1.72 :5.49)
3.06 (1.45 :
12.09)
2.70 (1.09 :
8.35)
1.94 (1.22 :
5.90)
IL-1α (pg/ml) 4.5 (1.9 :11.2)
15.7 (6.0 :
34.0)
3.3 (1.9 :
6.0)
3.7 (2.5 :
6.2)
CD34+KDR+ at visits 3 and 4 (Figure 2). In vivo the CD34+KDR+
phenotype is known to promote endothelial cell proliferation
and neovascularization and is considerd as one of the most
represented EPC phenotypes [24]. CD34+KDR+ cells were
increased in DFU patients when compared to at risk of DFU
patients (Table 2) and were reduced at the end of the study in
patients who healed their ulcers (Figure 2). Thus, it can be
hypothesized that wound healing requires early release of
CD34+KDR+ cells from the bone marrow while the subsequent
observed reduction could be associated with homing of these
cells to the ulcer area. However, although this hypothesis is in
agreement with animal studies [25], it cannot be proven by the
current study design and will need further investigation. Of
interest, an increase in the same phenotype has been
associated with a reduced risk of death from cardiovascular
causes [5].
SDF-1 plays an important role in angiogenesis and wound
healing. In conjunction with vascular endothelial growth factor
(VEGF)-A, it mobilizes EPCs from the bone marrow while
through its interaction with its receptor CXCR4 promotes the
homing of the EPCs to the wound area [26]. Although animal
studies have shown reduced SDF-1 expression in diabetic
cutaneous wounds and SDF-1 treatment has shown to reverse
the diabetic defect in EPC homing in diabetic mice [26], there is
limited information in DM patients. More recently, inhbition of
SDF-1 signaling has been linked to impaired healing by
Table 3 (continued).
 
Visit 1
(Baseline)
Visit 2 (4
weeks)
Visit 3 (8
weeks)
Visit 4 (12
weeks)
Interleukin-6 (pg/ml) 7.15 (3.61 :13.90)
4.02 (2.15 :
8.55)
2.5 (1.2 :
14.0)
3.4 (1.3 :
6.4)
IL-8 (pg/ml) 29.5 (17.1 :57.6)
17.7 (11.2 :
29.1)
29.4 (20.0 :
54.7)
22.2 (8.5 :
52.4)
Monocyte
Chemoattractant
Protein-1 (pg/ml)
605 (444 :
784)
722 (410 :
884)
531 (436 :
746)
638 (480 :
1012)
MDC (pg/ml) 1667 (1370 :1962)
1784 (1515 :
2168)
1730 (1473 :
1963)
1897 (1474 :
2645)
TNFα (pg/ml) 14.6 (10.8:22.0)
15.5 (8.2 :
18.9)
14.7 (8.5 :
18.2)
17.2 (11.2 :
20.6)
MMP-9 (ng/ml) 377 (272 :525)
339 (213 :
555)
306 (199 :
403)
337 (252 :
622)
E-Selectin (ng/ml) 38.9 (26.2 :55.1)
45.8 (27.2 :
60.7)
39.6 (26.4 :
49.9)
50.4 (31.9 :
68.6)
ICAM (ng/ml) 141 (109 :170)
141 (105 :
177)
130 (101 :
156)
143 (118 :
174)
VCAM (ng/ml) 1202 (1016 :1636)
1308 (1005 :
1811)
979 (851 :
1223)
1191 (967 :
1404)
CRP (μg/ml) 13.0 (5.0 :53.7)
11.0 (4.7 :
82.5)
25.0 (12.2 :
52.2)
16.0 (4.3 :
45.9)
As the data was nonparametrically distributed the Kruskal - Wallis test was
employed.
Median (25-75 interquartiles), flow cytometry results are presented as events/106
a: visit 1 vs visit 3.
doi: 10.1371/journal.pone.0083314.t003
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decreasing cellular migration and angiogenesis, modulation of
inflammatory cytokines and inflammation [27].Our data
indicates that serum SDF-1 levels were not affected by
diabetes or neuropathy but were increased in DM patients with
DFU (Table 2). A similar increase was also observed in the
serum stem cell factor (SCF) that is released by matrix
metalloproteinase-9 (MMP-9) and permits the transfer of
endothelial and hematopoietic stem cells from the quiescent to
proliferative niche (Table 2) [28]. Furthermore, in contrast to
animal studies [26], no reductions were observed in the
forearm and foot skin SDF-1 expression of DM patients while
the SDF-1 expression was higher in forearm stromal cells
(Figure 4). However, baseline SDF-1 and SCF serum levels
were not associated with complete wound healing or ulcer size
Figure 4.  A and B: Forearm skin biopsy staining for SDF-1in a diabetic patient (Figure 4A) and a healthy control subject
(Figure 4B), (frozen sections, x100).  SDF-1 was expressed by stromal cells (black arrows) and endothelial cells (red arrows) and
the staining pattern was mostly cytoplasmic and occasionally nuclear in cases of increased expression. The number of stained
stromal cells and the intensity of staining were increased in in diabetic patients while no difference was found in the number of
stained endothelial cells.
C and D: Foot skin staining for CXCR4 in a diabetic patient (Figure 4C) and a healthy control subject (Figure 4D) (frozen sections,
x200). CXCR4 was expressed by stromal cells (black arrows), endothelial cells (red arrows) and epithelial cells (blue arrows) and
the staining pattern was mostly membranar and cytoplasmic. The intensity of staining was higher in in the diabetic group (p<0.05)
but no differences were observed between the two groups in the number of positive stromal and endothelial cells (p=NS).
doi: 10.1371/journal.pone.0083314.g004
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reduction during the study period. A recent study that reported
increased levels of colony-forming units (CFU)-Hill EPCs in
type 1 DM patients with non-proliferative retinopathy found no
changes in serum SDF-1 levels [20]. Finally, no changes were
observed in the forearm and foot skin CXCR4 expression that
is also involved in wound healing [29].
DFU patients had higher levels of a number of inflammatory
cytokines, including IL-8, TNFα and CRP (Table 2) but only
lower levels of CRP were associated with complete wound
healing during the study (Figure 3A). CRP is an acute-phase
protein and its synthesis by the liver is rapidly dysregulated in
various conditions, including tissue damage and infection [30].
Our data suggest that local factors that affect wound healing,
such as tissue necrosis and infection may be better reflected
by the systemic CRP levels than any other inflammatory
cytokine. In addition, patients who healed their ulcers had lower
IL-1α at both the baseline and exit study visits (Figure 3B).
IL-1α, an acute-phase epidermal cytokine constitutively
produced by keratinocytes, and also produced by fibroblasts,
macrophages, and granulocytes, acts synergistically with TNF-
α in promoting inflammation [31]. GM-CSF, a proinflammatory
cytokine that is involved in inflammation, infection, production
of granulocytes and macrophages and on that has been used
for the treatment of chronic wounds [32] was increased at
baseline (Figure 3C). Our results are compatible with changes
that were observed in inflammatory cytokines in biopsies of
chronic venous ulcers that were collected before and after four
weeks of compression therapy [33]. Confirmation of these
results may lead to the use of CRP, IL-1α and GM-CSF as
prognostic markers for DFU healing.
The reduction in the DFU area during the study was
associated with FMD and serum sVCAM levels but not with any
measurement of the foot skin microvascular reactivity. These
results indicate that systemic changes are more important than
local changes in endothelial function for wound healing. Finally,
in contrast with previous studies, measurements of foot oxy
and deoxy-hemoglobin did not differ any of the groups and
were not associated with ulcer healing [14,34].
Various animal models of diabetic wound healing have been
tested as none of them is satisfactorily representative of the
human condition [15]. We studied EPC changes using the
same EPC markers as in the human study in diabetic mice and
rabbits before and after the wound creation. Our results
showed no EPC reduction in both diabetic animal models in
either study timepoints, before or ten days after wounding
(Table 4). Given that both animal models were devoid of any
serious complications, these results are consistent with the lack
of differences between healthy controls and diabetic patients
without complications and further emphasize the role of
diabetic complications in EPC measurements. Our results are
consistent with a previous study that reported no EPC changes
before and after wounding in mice with diabetes of four week
duration [35]. However, other studies that employed different
markers [26,36] have reported reduced circulating EPC in
diabetic mice, further emphasizing the need to compare similar
markers in both human and animal studies. In addition, EPCs
in both non-diabetic and diabetic rabbits tented to be lower ten
days post- wounding when compared to baseline, while these
cells tended to be higher in diabetic mice, indicating differences
between the two models with the rabbits being more
representative to human changes [15]. In agreement with the
human studies, mouse EPCs showed positive correlations with
markers of endothelial function, such as ICAM and VCAM,
raising the question whether impaired endothelial function
prevented homing. On the other hand, EPCs of non-diabetic
rabbits positively correlated with factors such as GM-CSF and
IL-8 that are known to influence EPC mobilization in humans
[37]. These results further emphasize the fact that no model is
completely satisfactory in representing the human condition
and the need to use multiple animal models.
Table 4. Flow cytometry results in the non-diabetic and diabetic mice and rabbit animal models before and ten days after
wounding.
 
C57BL/6 Mice Before
Wounding(CMB, n=34)
C57BL/6 Mice After
Wounding(CMW, n=7)
STZ-Diabetic C57BL/6 Mice Before
Wounding(DMB, n=11)
STZ-Diabetic C57BL/6 Mice After
Wounding(DMW, n=21)
CD34+FLK-1+ a 20 (0:81) 40 (10:220) 25 (10:150) 270 (130:600)
CD34+CD133+ b 0 (0:10) 30 (10:40) 10 (0:89) 40 (27:69)
FLK-1+CD133+ 80 (20:206) 140 (50:270) 128 (10:310) 210 (100:384)
CD34+FLK-1+CD133+ c 0 (0:13) 30 (10:40) 9 (0:50) 70 (64:150)
 Rabbits BeforeWounding(CRB, n=8)
Rabbits After Wounding(CRW,
n=7)
Alloxan-Diabetic Rabbits Before
Wounding(DRB, n=8)
Alloxan-Diabetic Rabbits After
Wounding(DRW, n=13)
CD34+ 132 (102:225) 146 (30:558) 665 (86:1956) 427 (249:3469)
CD34+KDR+ d 105 (55-163) 87 (39:272) 669 (110:1246) 273 (124:1134)
CD34+CD133+ e 0 (0:4) 4 (0:25) 63 (12:249) 39 (4:659)
KDR+CD133+ f 172 (108:251) 127 (58:152) 439 (359:887) 580 (59:1105)
CD34+KDR+CD133+ g 28 (2:35) 6 (0:24) 103 (12:238) 51 (10:167)
As the data was nonparametrically distributed the Kruskal - Wallis test was employed.
Flow cytometry results are presented as events/106
a: CMB vs DMB: p <0.05, DMB vs DMW: p<0.01; b: CMB vs CMW: p<0.05; c: CMB vs CMW: p <0.05, DMB vs DMW: p<0.01, CMW vs DMW: p<0.01; d: CRW vs DRW:
p<0.05; e: CRB vs DRB: p<0.05, CRW vs DRW: p<0.05; f: CRB vs DRB: p<0.05, CRB vs CRW: p<0.05; g: CRB vs DRB: p<0.05, CRW vs DRW: p<0.05.
doi: 10.1371/journal.pone.0083314.t004
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The present study has its limitations. The healing rate in the
DFU group was rather small, indicating that we included
patients with chronic wounds and limited healing capacity.
However, we believe that, as meaningful comparisons between
healers and non-healers were observed, the size of the group
did not affect the extraction of reliable conclusions. In addition,
although both groups with diabetic neuropathy tended to have
higher creatinine levels, we excluded patients with end stage
renal failure. This, in conjunction with the exclusion of patients
with macrovascular disease, drastically reduces the possibility
that renal or macrovascular complications were important
confounding factors in the observed results. Finally, we did not
apply statistical correction for multiple testing for the cytokine
measurements. The main reason is that cytokines are
influenced by the same factors and cannot be considered as
independent of each other. As a result, we believe that
applying statistical corrections in this study is not appropriate
and would carry a high potential of reporting erroneous false
negative results since this is not a clinical trial but rather a
study that focuses on the pathophysiology of wound healing.
In summary, our results indicate that EPCs are reduced in
diabetic patients at risk of DFU or patients with active DFU. In
addition, complete wound healing is associated with parallel
EPC reduction, suggesting possible increased homing.
Baseline CRP, IL-1α and GM-CSF were associated with
complete wound healing and may be helpful as prognostic
markers of DFU healing. Diabetic mice and rabbits do not
sufficiently represent the human EPC changes that occur
during diabetic wound healing, indicating the need of using
multiple animal models.
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